{
  "schemaVersion": 1,
  "id": "research-248",
  "slug": "248-what-pediatric-clinic-records-add-to-the-liraglutide-evidence",
  "title": "What pediatric clinic records add to the liraglutide evidence",
  "catalogLabel": "Liraglutide",
  "productCollection": "https://heritagebiolabs.com/research-library/products/liraglutide",
  "productHandles": [
    "liraglutide-702"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/liraglutide-702"
  ],
  "readingFocus": "Interpreting evidence",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 343,
  "sourceYears": [
    2025,
    2026
  ],
  "paragraphs": [
    "Peptides are short amino-acid chains linked by peptide bonds. Some can activate receptors that respond to hormones released after meals. Liraglutide is a modified peptide that activates the glucagon-like peptide-1, or GLP-1, receptor. In 2026, investigators examined health records to see how blood sugar measures changed in young people with type 2 diabetes who received liraglutide in a clinical setting. [1]",
    "The study used records from 2020 through 2023. It compared changes in HbA1c, a blood test that reflects average glucose exposure over the preceding months. At 26 weeks, the liraglutide group had a larger numerical decrease in HbA1c than the control group. The difference did not reach the study’s usual threshold for statistical significance. At 52 weeks, the comparison also did not establish a difference. Body mass index scores adjusted for age and sex were stable in both groups. [1]",
    "The authors found differences in some cholesterol measures, but those measurements were available in only a small subset of the participants. That matters for interpretation. The people whose charts contain a follow-up cholesterol test can differ from the people without one. The study’s analysis also involved different numbers of records at different time points. A missing measurement could reflect how the clinic scheduled tests or something about a patient’s course. [1]",
    "In this study, treatment choices were made in clinical practice. The investigators then looked back at what was recorded. This provides evidence about the outcomes that can be observed in a care setting. A randomized trial can better separate the effect of treatment assignment from the characteristics of the people who received it. The two methods answer related questions using different comparisons. [1]",
    "The U.S. Victoza label includes improving glycemic control in adults and children aged 10 years and older with type 2 diabetes, with diet and exercise. That indication is distinct from the weight-management indication for Saxenda, another liraglutide product with different eligibility. The 2026 observational analysis describes recorded glucose and cholesterol measures in young people with type 2 diabetes. Its results belong to that clinical question. [1, 2, 3]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "G. Castano Heredia et al. Real-world effectiveness of liraglutide in children with type 2 diabetes. Journal of the Endocrine Society (publication 2026-10-05).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42936196/"
    },
    {
      "number": 2,
      "citation": "U.S. Food and Drug Administration. VICTOZA (liraglutide) injection, prescribing information. Drugs@FDA (publication 2025-10).",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341s046lbl.pdf"
    },
    {
      "number": 3,
      "citation": "U.S. Food and Drug Administration. SAXENDA (liraglutide) injection, prescribing information. Drugs@FDA (publication 2025-10).",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206321s022lbl.pdf"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/248-what-pediatric-clinic-records-add-to-the-liraglutide-evidence",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/248-what-pediatric-clinic-records-add-to-the-liraglutide-evidence.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/248-what-pediatric-clinic-records-add-to-the-liraglutide-evidence.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 050 - Lipopeptide and Liraglutide.docx",
    "sourceArticleNumber": 248,
    "contentSha256": "9da11d128565403a9a87d41c2bc0be675393cc44869f8038681a2be6a95211a2",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
